

Media Release

Zug, 6 May 2022

Ad hoc announcement pursuant to Art. 53 Listing Rules

## **HBM Healthcare Investments year-end results 2021/2022**

**HBM Healthcare Investments reports a loss of CHF 78 million for the 2021/2022 financial year, for the first time in ten years and after a cumulative increase in value of 550 percent. The net asset value per share (NAV) fell by 3.6 percent and the share price by 13.2 percent due to globally declining market valuations of public companies, especially in the first quarter of 2022, triggered by rising inflation, interest rate hikes and increasing geopolitical uncertainty. The increase in value of the private companies' portfolio totalling CHF 129 million was unable to entirely compensate for this.**

**However, the healthcare market continues to offer an attractive investment universe and the prospects for HBM Healthcare's carefully constructed portfolio remain intact. The Company's solid financial position allows to continue its proven investment strategy and distribution policy.**

**The Board of Directors proposes to the Shareholders' Meeting a slight increase in the cash distribution of 20 cents to CHF 9.70 per share in the form of a par value repayment free of withholding tax.**

### **Annual loss of CHF 78 million due to declining market valuations**

HBM Healthcare Investments reports an annual loss of CHF 78 million for the 2021/2022 financial year. This is the first negative result in ten years, following the previous year's record profit.

In an increasingly challenging market environment, HBM Healthcare Investments initially performed very well. In January 2022, the Company reported a strong profit of CHF 275 million for the first nine months. Increases in the value of private companies and the rise in the share price of its largest investment – Cathay Biotech in China – offset the market-driven decline in the share prices of the other public investments. However, valuations of growth companies on the stock market came under increasing pressure against the backdrop of rising inflation and a first interest rate hike in the United States. The geopolitical events in Ukraine and the renewed flare-up of the Covid-19 pandemic in China further accentuated the price decline in public holdings in the final quarter of the financial year while the share price of Cathay Biotech also gave back some of its previous gains, which ultimately pushed our result into negative territory.

The individual components of the portfolio contributed as follows to the annual loss:

The value of the portfolio of private companies increased by a total of CHF 129 million. Financing rounds with external investors enabled an increase in the valuations of the

**HBM Healthcare Investments Ltd.**

Bundesplatz 1 CH-6300 Zug | Phone: +41 41 710 75 77 | [info@hbmhealthcare.com](mailto:info@hbmhealthcare.com) | [www.hbmhealthcare.com](http://www.hbmhealthcare.com)

Follow us on Twitter:  @HbmHealthcare

investments in Swixx Biopharma by CHF 75 million and ConnectRN by CHF 38 million. Both companies are operationally successful and experience strong sales growth. Furthermore, the acquisition of Bioshin by Biohaven resulted in a profit contribution of CHF 12 million. The value of the other investments combined increased by a total of CHF 4 million, net of higher valuations due to financing rounds as well as some value adjustments.

The fund portfolio decreased by CHF 35 million, mainly due to lower market prices of public companies held by these funds. Of this, CHF 12 million was attributable to HBM Genomics, CHF 10 million to WuXi Healthcare Ventures, and CHF 13 million to the other funds. Repayments totalling CHF 36 million were offset by capital calls of CHF 31 million. In total, CHF 5 million in liquidity flowed back from the funds. No new investment commitments were made to funds in the reporting year.

Public companies originating from the portfolio of private companies recorded market-related losses of CHF 82 million. Positive performers were Cathay Biotech (CHF 128 million, including dividend income of CHF 3 million and net of an increase in the provision for deferred tax on capital gain of CHF 14 million) and Harmony Biosciences (CHF 58 million). Both companies are profitable and report growing sales. The result was negatively impacted primarily by oncology companies with clinical development candidates, some of which had appreciated strongly in earlier years: BioAtla (CHF 62 million), ALX Oncology (CHF 32 million), Y-mAbs Therapeutics (CHF 28 million), Turning Point Therapeutics (CHF 27 million), Ambrx (CHF 20 million), Longboard Pharmaceuticals (CHF 20 million), Instil Bio (CHF 18 million), Connect Biopharma (CHF 13 million), IO Biotech (CHF 10 million) and other companies (CHF 38 million net). HBM Healthcare Investments had already realised substantial profits from most of these investments in the financial year just ended or in previous financial years. Clinical development is proceeding according to plan at most of these companies.

The portfolio of other public companies impaired the result by CHF 65 million. The investment in Biohaven developed positively, increasing by CHF 25 million. The result was burdened by the share price developments of Zymeworks (CHF 24 million), Esperion Therapeutics (CHF 12 million), Rocket Pharmaceuticals (CHF 11 million), ChemoCentryx (CHF 10 million) and various smaller investments (CHF 33 million net).

The hedging positions for currency and market risks resulted in a profit contribution of CHF 29 million. Other financial assets and financial instruments reduced the result by CHF 13 million, mainly due to currency effects.

Management fees, which depend on average net assets and market capitalisation, amounted to CHF 35 million. As the NAV did not exceed the high water mark at the end of the financial year, no performance-related compensation was due to the investment advisor or the Board of Directors. Other administrative costs and financial expenses were stable at less than CHF 6 million.

## Attractive portfolio with private and public companies

Taking into account the reported loss for the year and the par value repayment to shareholders last September, net assets decreased by CHF 0.17 billion to just under CHF 2 billion in the reporting year. As of 31 March 2022, total invested assets of CHF 2.2 billion were grouped as follows: private companies 28 percent, public companies 52 percent (public companies originating from the private companies' portfolio 37 percent), funds 8 percent, other assets 1 percent and cash and cash equivalents 11 percent. At less than 7 percent, the level of financial liabilities remains low.

On the balance sheet date, there were no hedges for currency or market risks.

## CHF 162 million invested in private companies

HBM Healthcare Investments invested CHF 93 million in eleven new private companies during the year under review. Of this amount, CHF 67 million has been paid in and CHF 26 million has been recognised as investment commitments. A further CHF 69 million was transferred to existing private companies as follow-on financings.

New investments made during the year are mentioned in the respective quarterly reports. No new investments were made in the reporting year's final quarter ended 31 March 2022. The three largest new investments in the 2021/2022 financial year are:

- The US company Upstream Bio received an investment commitment of USD 20 million (USD 11 million paid in). Upstream is developing an antibody to treat severe asthma.
- CHF 17 million went to the Swiss company Numab Therapeutics. Numab develops novel cancer immunotherapies based on its multispecific antibody discovery technology platform and has several partnerships with international pharmaceutical companies.
- USD 10 million was invested in Odyssey Therapeutics. The US-based company develops novel antibodies (V-bodies) for the treatment of cancer and for autoimmune therapies.

In addition to new investments in private companies, selective buying opportunities were also taken in new or existing public companies. For example, the sharp decline in the share price of Y-mAbs Therapeutics at the beginning of 2022 was used to double the position back to the original ownership stake. The investment in Sierra Oncology was significantly increased following positive phase III trial results for Momelotinib for the treatment of myelofibrosis patients. This decision was rewarded shortly after the balance sheet date, when GlaxoSmithKline announced the acquisition of Sierra Oncology for a total of USD 1.9 billion in mid-April.

## Increase of cash distribution to CHF 9.70 per share

HBM Healthcare's large increase in value in recent years, the positive outlook for its portfolio, and its solid financial position allow the Company to continue its distribution policy unchanged. Accordingly, over the long term, a portion of the increase in value achieved is to be returned to shareholders with a target yield ranging from 3 to 5 percent on the closing share price.

The Board of Directors proposes to the Shareholders' Meeting a slight increase in the cash distribution of 20 cents to CHF 9.70 per share in the form of a par value repayment free of withholding tax. Based on the share price of 31 March 2022, this corresponds to a yield of 3.5 percent.

Furthermore, the Board of Directors intends to propose a new share buy-back programme to the Shareholders' Meeting.

## Outlook

With inflation, rising interest rates and geopolitical uncertainty, the macroeconomic market environment has become more challenging in recent months. Nevertheless, HBM Healthcare Investments continues to rate the growth prospects for the healthcare sector and the factors central to its investment strategy as good.

The carefully compiled portfolio remains attractive in its composition and was supplemented with some interesting new investments in the reporting year. Many private companies are operationally successful and hold considerable added value potential. After the significant share price decline of the past twelve months, the segment of small and mid cap public companies is valued reasonably and will benefit from a market recovery. In addition, the progress of clinical development at these companies in the form of positive study results or market approvals should once again attract investor attention. Finally, Cathay Biotech, our largest holding, maintains its excellent position as one of the leading companies in the promising growth area of synthetic biology.

The current market environment offers increasingly interesting investment opportunities in the area of public companies, which we intend to exploit selectively. In addition, it can be assumed that strategic buyers will also follow this market development closely and – as demonstrated by GSK's recent acquisition of Sierra Oncology – this will again lead to an increase in acquisitions and strategic partnerships.

In the appendix to this media release you will find the balance sheet and income statement in accordance with IFRS, the portfolio details and an overview of the consolidated financials including a translation to the IFRS Financial Statements. The detailed Annual Report will be published on 18 May 2022 and will be available on the Company's website from that date onwards.

## Contact

For further information, please contact Dr. Andreas Wicki on +41 41 710 75 77, or at [andreas.wicki@hbmhealthcare.com](mailto:andreas.wicki@hbmhealthcare.com)

## About HBM Healthcare Investments

HBM Healthcare Investments invests in the healthcare sector. The Company holds and manages an international portfolio of promising companies in the human medicine, biotechnology, medical technology and diagnostics sectors and related areas. Many of these companies have their lead products already available on the market or at an advanced stage of development. The portfolio companies are closely tracked and actively guided in their strategic direction. This is what makes HBM Healthcare Investments an interesting alternative to investments in big pharma and biotechnology companies. HBM Healthcare Investments has an international shareholder base and is listed on SIX Swiss Exchange (ticker: HBMN).

## Disclaimer

The publication is for information purposes only and does not constitute an offer to sell or a solicitation to buy or subscribe for securities. This news release does not constitute a prospectus within the meaning of Art. 35ff FinSA, or securities prospectus in the sense of the German securities prospectus law. This news release and the information contained therein is not intended for distribution to the United States of America (USA) or within the USA and may not be distributed or forwarded to US persons (including legal persons) or to publications with a general distribution in the USA. This news release is not an offer or solicitation to buy securities in the United States. HBM Healthcare Investments AG's securities were not issued in accordance with the U.S. U.S. securities laws, and may not be sold, offered for sale, or delivered in the U.S. or to U.S. individuals without prior registration or without a registration exemption. Some information quoted was obtained from external sources HBM considers to be reliable. HBM cannot guarantee the adequacy, accuracy, timeliness or completeness of or be held responsible or liable for errors of fact regarding such data and information obtained from third parties, and this data may change with market conditions.

## Balance Sheet

Balance sheet (CHF 000)	Notes	31.3.2022	31.3.2021
<b>Assets</b>			
<b>Current assets</b>			
Cash and cash equivalents		5 388	6 033
Receivables		20	17
<b>Total current assets</b>		<b>5 408</b>	<b>6 050</b>
<b>Non-current assets</b>			
Investment in subsidiary	(3)	2 132 047	2 255 830
<b>Total non-current assets</b>		<b>2 132 047</b>	<b>2 255 830</b>
<b>Total assets</b>		<b>2 137 455</b>	<b>2 261 880</b>
<b>Liabilities</b>			
<b>Current liabilities</b>			
Financial liabilities	(4)	0	49 967
Liability from performance fee		0	8 154
Other liabilities		2 045	2 471
<b>Total current liabilities</b>		<b>2 045</b>	<b>60 592</b>
<b>Non-current liabilities</b>			
Financial liabilities	(4)	148 920	49 803
<b>Total non-current liabilities</b>		<b>148 920</b>	<b>49 803</b>
<b>Shareholders' equity</b>			
Share capital	(5.1)	203 928	290 928
Treasury shares	(5.2)	– 402	– 402
Capital reserve	(5.1)	142 173	142 137
Retained earnings		1 640 791	1 718 822
<b>Total shareholders' equity</b>		<b>1 986 490</b>	<b>2 151 485</b>
<b>Total liabilities and shareholders' equity</b>		<b>2 137 455</b>	<b>2 261 880</b>
Number of outstanding shares (in 000)		6 957	6 957
Net asset value (NAV) per share (CHF)		285.53	309.25

## Comprehensive Income

Statement of comprehensive income for the financial year ended 31 March (CHF 000)	Notes	2021/2022	2020/2021
Dividend income from investment in subsidiary	(3)	50 000	59 000
Net change in value of investment in subsidiary	(3)	– 123 783	709 780
<b>Result from investment activities</b>		<b>– 73 783</b>	<b>768 780</b>
Personnel expenses		– 750	– 9 295
Other operating expenses		– 781	– 742
<b>Result before interest and taxes</b>		<b>– 75 314</b>	<b>758 743</b>
Financial expenses		– 2 717	– 2 472
Financial income		0	0
Income taxes		0	0
<b>Net result for the year</b>		<b>– 78 031</b>	<b>756 271</b>
<b>Comprehensive result</b>		<b>– 78 031</b>	<b>756 271</b>
Number of outstanding shares, time-weighted (in 000)		6 957	6 957
Basic earnings per share (CHF)		– 11.22	108.71

As the Company does not have options or similar instruments outstanding, diluted earnings per share are identical to basic earnings per share.

## Investment in Subsidiary

The fair value of the investment in the Subsidiary HBM Healthcare Investments (Cayman) Ltd. developed as follows in the year under review:

Development fair value investment (CHF 000)	2021/2022	2020/2021
<b>Fair value at the beginning of financial year</b>	<b>2 255 830</b>	<b>1 546 050</b>
Change in value, gross	- 73 783	768 780
Dividend payment to parent company	- 50 000	- 59 000
<b>Fair value at the end of financial year</b>	<b>2 132 047</b>	<b>2 255 830</b>

Net assets of the investment in the Subsidiary comprised the following as at the balance sheet date:

Composition net assets (CHF 000)	Notes	31.3.2022	31.3.2021
Cash and cash equivalents		218 290	423 135
Receivables		29	161
Investments	(3.1)		
Private companies		614 348	446 199
Funds		175 915	216 601
Public companies		1 130 196	1 404 158
Shares of parent company		4 441	2 278
Financial instruments	(3.2)	1 512	0
Other financial assets	(3.3)	26 580	38 279
<b>Total assets</b>		<b>2 171 311</b>	<b>2 530 811</b>
Financial instruments	(3.2)	0	- 128 888
Liability from performance fee	(3.4)	0	- 120 664
Provision for deferred tax on capital gain and other taxes	(3.5)	- 38 534	- 24 725
Other current liabilities		- 730	- 704
<b>Total net assets at fair value</b>		<b>2 132 047</b>	<b>2 255 830</b>

During the reporting period, the net assets of the investment in the Subsidiary have developed as follows:

Change in net assets at fair value (CHF 000)	Notes	2021/2022	2020/2021
Net result on investments	(3.1)	- 43 302	986 925
Change in provision for deferred tax on capital gain and other taxes	(3.5)	- 13 809	- 7 556
Dividend income		3 403	374
Net result from financial instruments	(3.2)	31 574	- 67 672
Net result from other financial assets		- 15 363	- 767
Net result from shares of parent company		- 74	5 825
<b>Result from investing activities</b>		<b>- 37 571</b>	<b>917 129</b>
Management fee	(3.4)	- 34 920	- 26 326
Performance fee	(3.4)	0	- 120 664
Personnel and other operating expenses		- 1 296	- 1 355
Financial result		4	- 4
<b>Change in value, gross</b>		<b>- 73 783</b>	<b>768 780</b>
Dividend payment to parent company		- 50 000	- 59 000
<b>Net change in value of investment</b>		<b>- 123 783</b>	<b>709 780</b>



Private companies	Domicile	Investment currency	Amount disbursed 31.3.2021	Changes in reporting period	Amount disbursed 31.3.2022	Fair value 31.3.2022	Ownership 31.3.2022	Fair value 31.3.2022	Fair value 31.3.2021
		IC	IC million	IC million	IC million	IC million	%	CHF 000	CHF 000
Swixx BioPharma	CH	EUR	24.8	10.0	34.8	141.7	26.3	144 625	58 541
Neurelis	US	USD	24.4		24.4	56.2	10.5	51 869	53 055
ConnectRN	US	USD	5.9	8.0	13.9	52.1	21.7	48 024	2 279
NiKang Therapeutics	US	USD	5.0	15.0	20.0	25.2	5.3	23 290	4 718
Dren Bio	US	USD	3.7	11.2	14.9	22.7	7.8	20 960	3 515
Tata 1mg	IN	INR	1 178.6	-207.4	971.2	1 632.7	3.9	19 873	28 002
Fangzhou (Jianke)	CN	USD	19.9		19.9	19.7	6.0	18 203	18 619
Nuance Pharma	CN	USD	14.0		14.0	18.7	3.7	17 225	17 619
Numab Therapeutics	CH	CHF	0.0	17.0	17.0	17.0	6.5	17 000	0
SAI Life Sciences	IN	INR	449.0		449.0	1 343.9	5.5	16 359	17 346
FarmaLatam	PA	USD	14.8		14.8	17.7	44.7	16 329	16 703
Valo Health	US	USD	15.0		15.0	15.0	1.3	13 837	14 154
Karius	US	USD	10.0	5.0	15.0	15.0	4.9	13 837	9 436
Odyssey Therapeutics	US	USD	0.0	10.0	10.0	14.2	3.6	13 076	0
Adrenomed	DE	EUR	10.7	2.0	12.7	12.7	10.5	12 929	16 414
Sphingotec	DE	EUR	10.5	2.5	13.0	10.7	14.2	10 975	11 621
Upstream Bio	US	USD	0.0	11.0	11.0	11.0	6.5	10 148	0
Neuron23	US	USD	7.0	1.0	8.0	10.8	2.2	9 980	6 605
Genalyte (BaseHealth)	US	USD	7.5		7.5	10.2	3.5	9 426	9 642
River Renal	US	USD	10.0		10.0	10.0	12.5	9 225	9 436
Mineralys Therapeutics	US	USD	6.7	3.3	10.0	10.0	13.3	9 224	6 291
Aculys Pharma	JP	USD	0.0	6.0	6.0	9.9	4.8	9 139	0
Fore Biotherapeutics (NovellusDx)	IL	USD	3.3	5.7	9.0	9.0	10.4	8 303	3 088
Shape Memory Medical	US	USD	8.8		8.8	8.8	16.8	8 118	8 304
Valcare	IL	USD	5.1	0.7	5.8	8.5	8.0	7 867	7 429
Cure Everlife Holdings	MU	USD	5.6	3.3	8.9	8.4	9.3	7 775	5 099
Acrivon Therapeutics	US	USD	0.0	8.0	8.0	8.0	3.6	7 380	0
Visen Pharmaceuticals	CN	USD	7.5		7.5	7.5	0.6	6 919	7 077
Arrakis Therapeutics	US	USD	7.0		7.0	7.0	4.6	6 457	6 605
eGenesis Bio	US	USD	7.0		7.0	7.0	2.0	6 457	6 605
Cardialen	US	USD	5.0	1.5	6.5	6.5	17.8	5 996	4 718
FogPharma	US	USD	1.4	3.6	5.0	5.0	1.9	4 613	1 323
1000Farmacie	IT	EUR	0.0	4.0	4.0	4.0	14.6	4 084	0
Ignis Therapeutics	CN	USD	0.0	4.2	4.2	4.2	1.2	3 875	0
Mahzi Therapeutics	US	USD	0.0	4.0	4.0	4.0	5.2	3 690	0
MicroOptx	US	USD	3.0		3.0	3.0	8.3	2 767	2 831
Freenome Holdings	US	USD	0.0	3.0	3.0	3.0	0.2	2 767	0
Polyneuron Pharmaceuticals	CH	CHF	9.9		9.9	2.5	16.1	2 482	7 445
Vascular Dynamics	US	USD	12.5		12.5	2.7	9.1	2 450	2 946
C Ray Therapeutics	CN	USD	0.0	2.0	2.0	2.0	1.6	1 845	0
Antiva Biosciences	US	USD	0.0	1.5	1.5	1.5	1.8	1 384	0
Alydia Health <sup>1)</sup>	US	USD	3.0	-3.0	0.0	0.0	0.0	0	10 534
BioShin <sup>1)</sup>	CN	USD	8.0	-8.0	0.0	0.0	0.0	0	7 549
Others								3 566	4 787
<b>Total private companies</b>								<b>614 348</b>	<b>390 336</b>

1) The investments were sold during the reporting period.



Funds	Investment currency	Total commit- ment	Payments in reporting period	Repayments in reporting period	Cumulative payments 31.3.2022	Cumulative repayments 31.3.2022	Fair value 31.3.2022	Fair value 31.3.2022	Fair value 31.3.2021
	IC	IC million	IC million	IC million	IC million	IC million	IC million	CHF 000	CHF 000
HBM Genomics	USD	23.9	1.5		23.9	0.0	38.3	35 309	46 168
WuXi Healthcare Ventures II	USD	20.0	0.8	2.0	20.0	4.0	24.9	22 982	34 092
MedFocus Fund II	USD	26.0			26.0	25.0	23.7	21 868	22 829
6 Dimensions Capital	USD	25.0	1.3	23.0	25.0	26.0	23.4	21 594	43 713
120 Capital	USD	25.0	13.8		13.8	0.0	13.1	12 107	0
C-Bridge Healthcare Fund IV	USD	10.0	2.5		9.7	0.2	11.7	10 839	9 274
HBM BioCapital II <sup>1)</sup>	EUR	42.0	1.0	8.6	46.1	21.8	10.6	10 792	21 417
Tata Capital HBM Fund I	USD	10.0	0.2		9.9	6.9	6.3	5 807	5 534
LYZZ Capital Fund II	USD	15.0	0.9		5.6	0.0	6.0	5 517	4 411
C-Bridge Healthcare Fund V	USD	15.0	4.1	0.5	5.6	0.5	4.7	4 315	1 333
Hatteras Venture Partners III	USD	10.0		0.9	10.2	2.9	4.3	4 001	5 986
Galen Partners V	USD	10.0			10.4	8.8	4.2	3 836	7 291
Tata Capital Healthcare Fund II	USD	20.0	2.7	0.8	5.8	0.8	4.1	3 824	2 150
HBM Genomics II	USD	15.0	4.0		4.0	0.0	3.7	3 406	0
BioVeda China IV	USD	5.0		0.4	4.0	0.9	3.5	3 234	3 316
BioMedInvest II	CHF	10.0		0.5	10.0	3.9	3.0	3 030	4 840
BioMedInvest I	CHF	26.0		0.5	26.0	27.6	1.7	1 742	2 184
Nordic Biotech	DKK	31.0			31.0	221.7	8.1	1 116	1 241
Others								596	822
<b>Total funds</b>								<b>175 915</b>	<b>216 601</b>

1) The fair value of EUR 10.6 million takes into account the fund's cumulative management fees of EUR 6.0 million. This amount has been reimbursed in full to HBM Healthcare so that fees are not levied twice.

Public companies	Invest- ment currency	Balance 31.3.2021	Changes in reporting period	Balance 31.3.2022	Share price 31.3.2022	Ownership 31.3.2022	Fair value 31.3.2022	Fair value 31.3.2021
	IC	Number of shares	Number of shares	Number of shares	IC	%	CHF 000	CHF 000
<b>Companies originating from private companies portfolio</b>								
Cathay Biotech <sup>1)</sup>	CNY	29610798	0	29610798	100.01	7.1	430 884	292 323
Harmony Biosciences	USD	4641 779	– 978 551	3 663 228	48.65	6.2	164 404	144 715
Y-mAbs Therapeutics	USD	1 972 751	1 718 203	3 690 954	11.88	8.4	40 450	56 291
Pacira BioSciences	USD	451 324	0	451 324	76.32	1.0	31 776	29 849
Monte Rosa Therapeutics <sup>2)</sup>	USD	1 798 516	0	1 798 516	14.02	3.9	23 261	17 757
Arcutis	USD	940 424	8 242	948 666	19.26	1.9	16 855	25 672
Turning Point Therapeutics	USD	285 664	347 856	633 520	26.85	1.3	15 692	25 497
IO Biotech <sup>2)</sup>	USD	891 706	1 528 778	2 420 484	5.30	8.4	11 834	8 854
Instil Bio	USD	2 192 908	– 1 138 995	1 053 913	10.75	0.8	10 452	51 896
Longboard Pharmaceuticals	USD	1 880 000	0	1 880 000	5.34	11.1	9 261	29 058
Ambrx Biopharma <sup>2)</sup>	USD	1 736 389	671 692	2 408 081	4.12	6.9	9 152	18 872
ALX Oncology	USD	937 998	– 357 604	580 394	16.90	1.4	9 048	65 267
BioAtla	USD	1 715 869	– 288 552	1 427 317	5.00	4.0	6 583	82 315
Others							13 195	156 852
Total companies originating from private companies portfolio							792 847	1 005 218
<b>Various companies</b>								
Biohaven Pharmaceuticals	USD	507 523	– 79 429	428 094	118.57	0.6	46 825	32 733
Sierra Oncology	USD	80 706	666 517	747 223	32.05	3.2	22 092	1 312
Laurus Labs	INR	3 669 033	– 976 009	2 693 024	590.10	0.5	19 343	17 142
Argenx (ADR)	USD	90 000	– 30 000	60 000	315.31	0.1	17 452	23 387
BioInvent	SEK	3 630 840	354 364	3 985 204	44.38	6.8	17 362	18 523
Argenx	EUR	90 000	– 30 000	60 000	282.50	0.1	17 305	23 350
ChemoCentryx	USD	306 525	433 317	739 842	25.07	1.0	17 110	14 821
Hutchmed China	HKD	0	3 890 000	3 890 000	30.10	0.5	13 790	0
Iovance	USD	163 433	619 490	782 923	16.65	0.5	12 025	4 882
Dishman Carbogen	INR	2 543 633	2 396 335	4 939 968	184.75	3.2	11 109	3 578
Aurobindo Pharma	INR	220 000	1 131 002	1 351 002	668.55	0.2	10 994	2 502
Zymeworks	USD	964 535	798 837	1 763 372	6.55	3.1	10 655	28 742
Vicore Pharma	SEK	2 850 000	1 770 302	4 620 302	22.65	6.4	10 273	8 163
Beigene	HKD	700 000	0	700 000	121.20	0.1	9 992	17 095
Blueprint Medicines	USD	0	145 000	145 000	63.88	0.2	8 545	0
Rocket Pharmaceuticals	USD	177 461	400 618	578 079	15.86	0.9	8 458	7 430
Mirati Therapeutics	USD	0	111 404	111 404	82.22	0.2	8 450	0
Index Pharmaceuticals	SEK	52 916 667	0	52 916 667	1.45	9.9	7 512	9 769
Guangzhou Baiyunshan	HKD	2 609 000	0	2 609 000	20.75	0.2	6 376	5 972
Nicox	EUR	26 191 102	400 000	30 191 102	1.96	7.0	6 041	12 349
Affimed	USD	0	1 327 597	1 327 597	4.37	1.1	5 352	0
Insmed	USD	0	236 167	236 167	23.50	0.2	5 120	0
Others							45 168	223 053
Total various companies							337 349	454 803
<b>Total public companies</b>							<b>1 130 196</b>	<b>1 460 021</b>
<b>Total investments</b>							<b>1 920 459</b>	<b>2 066 958</b>

1) The tax on capital gain and other taxes which may be owed in China upon the sale of the investment are accrued separately (note 3.5). The shares are subject to a holding period until August 2023 and the disclosed fair value of the investment includes a

lock-up discount. The share price of CNY 109.00 as at 31.3.2022 was adjusted by a discount of 8.25 percent to CNY 100.01.

2) The companies went public on US NASDAQ during the reporting period. The investments were listed under private companies in previous reports.

## Balance Sheet

Balance sheet (CHF 000)	Notes to IFRS Group Financial Statements <sup>1)</sup>	Consolidated Financials <sup>2)</sup> 31.3.2022 (unaudited)	Translation <sup>3)</sup>	IFRS Group Finan- cial Statements 31.3.2022 (audited)
<b>Assets</b>				
<b>Current assets</b>				
Cash and cash equivalents		223 678	– 218 290	5 388
Receivables		49	– 29	20
Financial instruments	(3.2)	1 512	– 1 512	0
<b>Total current assets</b>		<b>225 239</b>	<b>– 219 831</b>	<b>5 408</b>
<b>Non-current assets</b>				
Investments	(3.1)	1 920 459	– 1 920 459	0
Other financial assets	(3.3)	26 580	– 26 580	0
Investment in subsidiary		0	2 132 047	2 132 047
<b>Total non-current assets</b>		<b>1 947 039</b>	<b>185 008</b>	<b>2 132 047</b>
<b>Total assets</b>		<b>2 172 278</b>	<b>– 34 823</b>	<b>2 137 455</b>
<b>Liabilities</b>				
<b>Current liabilities</b>				
Other liabilities		2 775	– 730	2 045
<b>Total current liabilities</b>		<b>2 775</b>	<b>– 730</b>	<b>2 045</b>
<b>Non-current liabilities</b>				
Provision for deferred tax on capital gain and other taxes	(3.5)	38 534	– 38 534	0
Financial liabilities	(4)	148 920	0	148 920
<b>Total non-current liabilities</b>		<b>187 454</b>	<b>– 38 534</b>	<b>148 920</b>
<b>Shareholders' equity</b>				
Share capital		203 928	0	203 928
Treasury shares		– 5 196	4 794	– 402
Capital reserve		158 238	– 16 065	142 173
Retained earnings		1 625 079	15 712	1 640 791
<b>Total shareholders' equity</b>		<b>1 982 049</b>	<b>4 441</b>	<b>1 986 490</b>
<b>Total liabilities and shareholders' equity</b>		<b>2 172 278</b>	<b>– 34 823</b>	<b>2 137 455</b>
Number of outstanding shares (in 000)		6 941	16	6 957
Net asset value (NAV) per share (CHF)		285.56		285.53

1) Details on the individual items can be found in the notes to the audited IFRS Group Financial Statements of the annual report.

2) Consolidated financials of the HBM Healthcare Group with full consolidation of the subsidiary HBM Healthcare Investments (Cayman) Ltd., Cayman Islands, and its subsidiary HBM Private Equity India Ltd, Republic of Mauritius.

3) Reconciliation to the audited IFRS Group Financial Statements. Based on IFRS 10, the subsidiary is not consolidated, but is

valued individually at fair value through profit and loss. The differences in equity and net profit for the year result from the shares of the parent company held by the subsidiary. In the consolidated financial statements, these are deducted from equity at their acquisition cost. In the IFRS Group Financial Statements, they are valued at fair value through profit and loss by the subsidiary.

## Comprehensive Income

Statement of comprehensive income for the financial year ended 31 March (CHF 000)	Notes to IFRS Group Financial Statements <sup>1)</sup>	Consolidated Financials <sup>2)</sup> 2021/2022 (unaudited)	Translation <sup>3)</sup>	IFRS Group Finan- cial Statements 2021/2022 (audited)
Net result on investments	(3.1)	-43 302	43 302	0
Change in provision for deferred tax on capital gain and other taxes	(3.5)	-13 809	13 809	0
Dividend income		3 403	-3 403	0
Net result from financial instruments	(3.2)	31 574	-31 574	0
Net result from other financial assets		-15 363	15 363	0
Dividend income from investment in subsidiary		0	50 000	50 000
Net change in value of investment in subsidiary		0	-123 783	-123 783
<b>Result from investment activities</b>		<b>-37 497</b>	<b>-36 286</b>	<b>-73 783</b>
Management fee	(3.4)	-34 920	34 920	0
Performance fee	(3.4)	-1 678	928	-750
Personnel expenses	(6)	-1 149	368	-781
Other operating expenses				
<b>Result before interest and taxes</b>		<b>-75 244</b>	<b>-70</b>	<b>-75 314</b>
Financial expenses		-2 720	3	-2 717
Financial income		7	-7	0
Income taxes		0	0	0
<b>Net result for the year</b>		<b>-77 957</b>	<b>-74</b>	<b>-78 031</b>
<b>Comprehensive result</b>		<b>-77 957</b>	<b>-74</b>	<b>-78 031</b>
Number of outstanding shares, time-weighted (in 000)		6 951	6	6 957
Basic earnings per share (CHF)		-11.22		-11.22

For the footnotes, see previous page.